

The following medications, typically administered in a provider's office or ambulatory/outpatient infusion center, require authorization prior to utilization. Authorization requests can be submitted via the Portal. Additionally, you are welcome to call our member services line to initiate the Prior Authorization process.

This list is updated no more than quarterly.

Effective date: 7/1/2023

| Therapeutic category | Brand Name | Generic Name | HCPCS |
|--|----------------------|------------------------------|---|
| CAR-T Therapy | Abecma | idecabtagene vicleucel | Q2055; inpatient admin |
| Antineoplastic agent | Abraxane | paclitaxel protein-bound | J9264 |
| Immunologic agent | Actemra, IV infusion | tocilizumab | J3262 |
| Adrenocorticotropin Stimulating Hormone | Acthar HP | corticotropin | J0800 |
| Anti-P-selectin; monoclonal antibody | Adakveo | crizanlizumab-tmca | J0791 |
| Antineoplastic agent | Adcetris | brentuximab vedotin | J9042 |
| Anti-amyloid monoclonal antibody (Alzhei | Aduhelm | aducanumab | J0172: NOT COVERED |
| Enzyme replacement drug | Aldurazyme | laronidate | J1931 |
| Antineoplastic agent | Alimta | pemetrexed | J9305, J9314 ^a , J9294 ^a , J9296 ^a , J9297 ^a |
| Antineoplastic agent | Aliqopa | copanlisib | J9057 |
| Antineoplastic agent | Alymsys | bevacizumab-maly | Q5126 |
| Muscular dystrophy drug | Amondys 45 | casimersen | J1426 |
| Anti-Transthyretin siRNA agent | Amvuttra | Vutrisiran | J0225 |
| Antitrypsin deficiency agent | Aralast NP | alpha-1 proteinase inhibitor | J0256 |
| Erythropoiesis stimulating agent | Aranesp | darbepoetin alfa | J0881 |
| Erythropoiesis stimulating agent | Aranesp | darbepoetin alfa | J0882 |
| IL-1 inhibitor; CAP syndromes | Arcalyst | rilonacept | J2793 |
| Antineoplastic agent | Arranon | nelarabine | J9261 |
| Antineoplastic agent | Arzerra | ofatumumab | J9302 |
| Immunoglobulin | Asceniv | immune globulin | J1554 |
| Antineoplastic agent | Asparlas | calaspargase pegol-mknl | J9118 |
| Antineoplastic | Avastin | bevacizumab | J9035 [#] |
| Ophthalmic injectable | Avastin | bevacizumab | new ophthalmic inj code C9257 (6/1/23) |
| Immunologic agent | Avsola | infliximab-axxq | Q5121 |

| | | | |
|---|-----------------|------------------------------------|-------------------------------|
| PD1-PDL1 drug | Bavencio | avelumab | J9023 |
| Antineoplastic agent | Beleodaq | belinostat | J9032 |
| Antineoplastic agent | Belrapzo | bendamustine HCl | J9036 |
| Antineoplastic agent | Bendeka | bendamustine HCl | J9034 |
| Systemic lupus erythematosus (SLE) drug | Benlysta | belimumab | J0490 |
| Ophthalmic injectable | Beovu | brolicizumab-dbli | J0179 |
| Hereditary angioedema medication | Berinert | C1 esterase inhibitor | J0597 |
| Antineoplastic agent | Besponsa | inotuzumab ozogamicin | J9229 |
| Immunoglobulin | Bivigam | immune globulin | J1556 |
| Antineoplastic agent | Blenrep | belantamab mafodotin | J9037 |
| Antineoplastic agent | Blinicyto | blinatumomab | J9039 |
| Botulinum toxins | Botox | onabotulinumtoxin A | J0585 |
| CAR-T Therapy | Breyanzi | lisocabtagene maraleucal | Q2054; inpt admin |
| Enzyme replacement drug | Brineura | cerliponse alfa | J0567 |
| Multiple sclerosis drug | Briumvi | ublituximab | J2329 (new code as of 7/1/23) |
| Ophthalmic injectable | Byooviz | ranibizumab-nuna | Q5124 |
| HIV-medication, injectable | Cabenuva | cabotegravir rilpivirine | J0741 |
| Immunoglobulin | Carimune NF | immune globulin | J1566 |
| Enzyme replacement drug | Cerezyme | imiglucerase | J1786 |
| Ophthalmic injectable | Cimerli | ranibizumab | Q5128 |
| Respiratory injectable | Cinqair | reslizumab | J2786 |
| Hereditary angioedema medication | Cinryze | C1 esterase inhibitor | J0598 |
| Antineoplastic agent | Cosela | trilaciclin | J1448 (*new 10/1/21) |
| Anti-FGF23 monoclonal antibody | Crysvita | burosumab-twza | J0584 |
| Immunoglobulin | Cutaquig | SC immune globulin | J7799 |
| Immunoglobulin | Cuvitru | SC immune globulin | J1555 |
| Antineoplastic agent | Cyramza | ramucirumab | J9308 |
| Antineoplastic agent | Danyelza | naxitamab-gqgk | J9348 |
| Antineoplastic agent | Darzalex | daratumumab | J9145 |
| Antineoplastic agent | Darzalex Faspro | daratumumab and hyaluronidase-fihj | J9144 |
| Hyaluronic Acid agents | Durolane | hyaluronate derivative | J7318 |
| Botulinum toxins | Dysport | abobotulinumtoxin B | J0586 |
| Antineoplastic agent | Elahere | mirvetuximab soravtansine | J9999 (non-specific)/C9146 |

| | | | |
|--|--------------------------|---------------------------------|--|
| Enzyme replacement drug | Elaprase | idursulfase | J1743 |
| Enzyme replacement drug | Elelyso | taliglucerase alfa | J3060 |
| Urate-Oxidase enzyme | Elitek | rasburicase | J2783 |
| Antineoplastic agent | Elzonris | tagraxofusp-erzs | J9269 |
| Antineoplastic agent | Empliciti | elotuzumab | J9176 |
| HER-2 receptor drug | Enhertu | fam-trastuzumab deruxtecan-nxki | J9358 |
| Immunologic agent | Entyvio | vedolizumab | J3380 |
| Erythropoiesis stimulating agent | Epogen | epoetin alfa | J0885 |
| Erythropoiesis stimulating agent | Epogen | epoetin alfa | J0886 |
| Antineoplastic agent | Erbitux | cetuximab | J9055 |
| Antineoplastic enzyme | Erwinaze | asparaginase erwina | J9019 |
| Hyaluronic Acid agents | Euflexxa | sodium hyaluronate | J7323 |
| Sclerostin inhibitor | Evenity | romosozumab | J3111 |
| Antilipemic agent | Evkeeza | evinacumab | J1305 |
| Muscular dystrophy drug | Exondys 51 | eteplirsen | J1428 |
| Ophthalmic injectable | Eylea | aflibercept | J0178 |
| Enzyme replacement drug | Fabrazyme | agalsidase beta | J0180 |
| Respiratory injectable | Fasenra | benralizumab | J0517 |
| Antineoplastic agent | Faslodex | fulvestrant | J9395, J9393 ^a , J9394 ^a |
| Iron product | Feraheme | ferumoxytol | Q0138 non-ESRD/Q0139 ESRD on dialysis |
| Hereditary angioedema medication | Firazyr | icatibant | J1744 |
| Immunoglobulin | Flebogamma | immune globulin | J1572 |
| Pulmonary arteriolar hypertension drug | Flolan, IV infusion | epoprostenol sodium | J1325 |
| Antineoplastic agent | Folotyn | pralatrexate | J9307 |
| Antineoplastic, rescue agent | Fusilev | levoleucovorin | J0641 |
| Monoclonal antibody | Gamifant | emapalumab-lzsg | J9210 |
| Immunoglobulin | Gammagard, Gammagard S/D | immune globulin | J1569 |
| Immunoglobulin | Gammaked | immune globulin | J1561 |
| Immunoglobulin | Gammaked | SC immune globulin | J1561 |
| Immunoglobulin | Gammaplex | immune globulin | J1557 |
| Immunoglobulin | Gamunex-C | immune globulin | J1561 |
| Antineoplastic agent | Gazyva | obinutuzumab | J9301 |
| Hyaluronic Acid agents | Gel-One | hyaluronate, cross-linked | J7326 |

| | | | |
|---|-------------------|------------------------------------|----------------------------|
| Hyaluronic Acid agents | Gelsyn-3 | sodium hyaluronate | J7328 |
| Hyaluronic Acid agents | GenVisc 850 | sodium hyaluronate | J7320 |
| Aminolevulinic Synthase 1-Directed Sma | Givlaari | givosiran | J0223 |
| Antitrypsin deficiency agent | Glassia | alpha-1 proteinase inhibitor | J0257 |
| Granulocyte-colony stimulating factor | Granix | filgrastim | J1447 |
| Hereditary angioedema medication | Haegarda | C1 esterase inhibitor | J0599 |
| Antineoplastic agent | Halaven | eribulin | J9179 |
| Gene-therapy; antihemophilic agent | Hemgenix | etranacogene dezaparvovec-drlb | J1411 (new 4.1.23) |
| HER-2 receptor drug | Herceptin | trastuzumab | J9355 |
| HER-2 receptor drug | Herceptin Hylecta | trastuzumab and hyaluronidase-oysk | J9356 |
| HER-2 receptor drug | Herzuma | trastuzumab-pkrb | Q5113 |
| Immunoglobulin | Hizentra | SC immune globulin | J1559 |
| Hyaluronic Acid agents | Hyalgan | sodium hyaluronate | J7321 |
| Hyaluronic Acid agents | Hymovis | hyaluronan | J7322 |
| Immunoglobulin | HyQvia | SC immune globulin | J1575 |
| IL-1 beta inhibitor | Ilaris | canakinumab | J0638 |
| Immunologic agent - antipsoriatic, IL-23 in | Ilumya | tildrakizumab-asmn | J3245 |
| Corticosteroid, ophthalmic | Iluvien | fluocinonide acetate implant | J7313 |
| PD1-PDL1 drug | Imfinzi | durvalumab | J9173 |
| Antineoplastic agent | Imjudo | tremelimumab | J9999 (non-specific)/C9147 |
| Antineoplastic agent | Imlygic | talimogene laherparepvec | J9325 |
| Immunologic agent | Inflectra | infliximab-dyyb | Q5103 |
| Iron product | Injectafer | ferric carboxymaltose | J1439 |
| Antineoplastic agent | Istodax | romidepsin | J9315 |
| Antineoplastic agent | Ixempra | ixabepilone | J9207 |
| Antineoplastic agent | Jelmyto | mitomycin ureteral gel | J9281 |
| Antineoplastic agent | Jemperli | dostarlimab-gxly | J9272 |
| Antineoplastic agent | Jevtana | cabazitaxel | J9043 |
| HER-2 receptor drug | Kadcyla | ado-trastuzumab emtansine | J9354 |
| Hereditary angioedema medication | Kalbitor | ecallantie | J1290 |
| HER-2 receptor drug | Kanjinti | trastuzumab-anns | Q5117 |
| Enzyme replacement drug | Kanuma | sebelipase alfa | J2840 |
| Chemoprotective agent | Kepivance | palifermin | J2425 |

| | | | |
|---------------------------------------|------------|------------------------------------|---------------------------|
| PD1-PDL1 drug | Keytruda | pembrolizumab | J9271 |
| Antineoplastic, rescue agent | Khapzory | levoleucovorin | J0642 |
| Gout medication | Krystexxa | pegloticase | J2507 |
| Intrauterine device, contraceptive | Kyleena | levonorgestrel intrauterine device | J7296 ¹ |
| CAR-T Therapy | Kymriah | tisagenlecleucel | Q2042;inpatient admin |
| Antineoplastic agent | Kyprolis | carfilzomib | J9047 |
| Antineoplastic agent | Lartruvo | olaratumab | J9285 |
| Multiple sclerosis drug | Lemtrada | alemtuzumab | J0202 |
| Antilipemic agent | Leqvio | inclisiran | J1306 |
| PD1-PDL1 drug | Libtayo | cemiplimab-rwlc | J9119 |
| Intrauterine device, contraceptive | Liletta | levonorgestrel intrauterine device | J7297 ¹ |
| Ophthalmic injectable | Lucentis | ranibizumab | J2778 |
| Enzyme replacement drug | Lumizyme | alglucosidase alfa | J0221 |
| Antineoplastic agent | Lumoxiti | moxetumomab pasudotox-tdfk | J9313 |
| Ophthalmic injectable | Luxturna | voretigene neparvovex-rzyl | J3398 |
| Ophthalmic injectable | Macugen | pegaptanib | J2503 |
| Antineoplastic agent | Margenza | margetuximab-cmkb | J9353 |
| Antineoplastic agent | Marqibo | vincristine liposomal | J9371 |
| Enzyme replacement drug | Mepsevii | vestronidase alfa-vjbk | J3397 |
| Erythropoiesis stimulating agent | Mircera | epoetin alfa | J0888(ND)/J0887(dialysis) |
| Intrauterine device, contraceptive | Mirena | levonorgestrel intrauterine device | J7298 ¹ |
| Antineoplastic agent | Monjuvi | tafasitamab-cxix | J9349 |
| Iron product | Monoferric | ferric derisomaltose | J1437 |
| Hyaluronic Acid agents | Monovisc | hyaluronan | J7327 |
| Hematopoietic stem cell mobilizer | Mozobil | plerixafor | J2562 |
| Antineoplastic agent | Mvasi | bevacizumab-awwb | Q5107 |
| Antineoplastic agent | Mylotarg | gemtuzumab ozogamicin | J9203 |
| Botulinum toxins | Myobloc | rimabotulinumtoxin B | J0587 |
| Enzyme replacement drug | Naglazyme | galsulfase | J1458 |
| Granulocyte-colony stimulating factor | Neulasta | pegfilgrastim-jmdb | J2506 |
| Granulocyte-colony stimulating factor | Neupogen | filgrastim | J1442 |
| Granulocyte-colony stimulating factor | Nplate | romiplostim | J2796 |
| Respiratory injectable | Nucala | mepolizumab | J2182 |

| | | | |
|--|-----------------------|--|----------------------|
| Selective T-cell costimulation blocker | Nulojix | belatacept | J0485 |
| Multiple sclerosis drug | Ocrevus | ocrelizumab | J2350 |
| Immunoglobulin | Octagam | immune globulin | J1568 |
| HER-2 receptor drug | Ogivri | trastuzumab-dkst | Q5114 |
| Antineoplastic agent | Oncaspar | pegaspargase | J9266 |
| Antineoplastic agent | Onivyde | irinotecan liposome | J9205 |
| Polyneuropathy drug | Onpattro | patisiran | J0222 |
| HER-2 receptor drug | Ontruzant | trastuzumab-dttb | Q5112 |
| PD1-PDL1 drug | Opdivo | nivolumab | J9299 |
| Antineoplastic agent | Opudalag | nivolumab and relatlimab | J9298 |
| Immunologic agent | Orencia, IV infusion | abatacept | J0129 |
| Hyaluronic Acid agents | Orthovisc | hyaluronan | J7324 |
| Hydroxyacid Oxidase 1 (HAO1)-Directed Sr | Oxlumo | lumasiran | J0224 |
| Ophthalmic corticosteroid insert | Ozurdex | dexamethasone ophthalmic insert | J7312 |
| Antineoplastic agent | Padcev | enfortumab vedotin | J9177 |
| Immunoglobulin | Panzyga | immune globulin | J1599 |
| Antineoplastic agent | Pepaxto | melphalan flufenamide | J9247 (*new 10/1/21) |
| HER-2 receptor drug | Perjeta | pertuzumab | J9306 |
| Antineoplastic agent | Phesgo | pertuzumab, trastuzumab, hyaluronidase | J9316 |
| Antineoplastic agent | Polivy | polatuzumab vedotin-piiq | J9309 |
| Antineoplastic agent | Portrazza | necitumumab | J9295 |
| Antineoplastic agent | Poteligeo | mogamulizumab | J9204 |
| Analgesic, nonopioid | Prialt | ziconotide | J2278 |
| Immunoglobulin | Privigen | immune globulin | J1459 |
| Erythropoiesis stimulating agent | Procrit | epoetin alfa | J0885 |
| Erythropoiesis stimulating agent | Procrit | epoetin alfa | J0886 |
| Antitrypsin deficiency agent | Prolastin/Prolastin-C | alpha-1 proteinase inhibitor | J0256 |
| Antineoplastic agent | Proleukin | aldesleukin, IL-2 | J9015 |
| Osteoporosis drug | Prolia | denosumab | J0897 |
| Cellular immunotherapy | Provenge | sipuleucel-T | Q2043 |
| Amyotrophic lateral sclerosis (ALS) drug | Radicava | edaravone | J1301 |
| Hematopoietic agent, activin receptor liga | Reblozyl | luspatercept-aamt | J0896 |
| Osteoporosis drug | Reclast | zoledronic acid | J3489 |
| Immunologic agent | Remicade | infliximab | J1745 |

| | | | |
|---|---------------------------|------------------------------------|--|
| Immunologic agent | Renflexis | infliximab-abda | Q5104 |
| Erythropoiesis stimulating agent | Retacrit | recombinant human erythropoietin | Q5106 non-ESRD |
| Erythropoiesis stimulating agent | Retacrit | recombinant human erythropoietin | Q5105 ESRD-on dialysis |
| Corticosteroid, ophthalmic | Retisert | fluocinonide acetone implant | J7311 |
| Immunologic agent | Riabni | rituximab-arrx | Q5123 |
| Immunologic agent | Rituxan | rituximab | J9312 |
| Immunologic agent | Rituxan Hycela | rituximab and hyaluronidase human | J9311 |
| Hereditary angioedema medication | Ruconest | C1 esterase inhibitor | J0596 |
| Immunologic agent | Ruxience | rituximab-pvvr | Q5119 |
| Antineoplastic agent | Rybrevant | amivantamab | J9061 |
| Somatostatin Analog | Sandostatin LAR | octreotide acetate | J2353 |
| Antineoplastic agent | Sarclisa | isatuximab-irfc | J9227 |
| Alpha-Melanocyte Stimulating Hormone A | Scenesse | afamelanotide | J7352 |
| Immunologic agent | Simponi Aria, IV infusion | golimumab | J1602 |
| Intrauterine device, contraceptive | Skyla | levonorgestrel intrauterine device | J7301 ¹ |
| Immunologic agent | Skyrizi | risankizumab | J2327 |
| Complement Inhibitor, monoclonal antibody | Soliris | eculizumab | J1300 |
| Spinal muscular atrophy | Spinraza | nusinersen | J2326 |
| Antidepressant | Spravato | esketamine, intranasal | G2082 (<56mg)/G2083 (>56mg) (J3490 non-specific) |
| Immunologic agent | Stelara, IV infusion | ustekinumab | J3358 |
| Hyaluronic Acid agents | Supartz/Supartz FX | sodium hyaluronate | J7321 |
| Gonadotropin-releasing hormone agonist | Supprelin LA | histrelin | J9226 |
| Antiemetics, IV admin | Sustol | granisetron, extended-release | J1627 |
| Ophthalmic injectable | Susvimo | ranibizumab | J2779 |
| Antineoplastic agent | Sylvant | siltuximab | J2860 |
| Hyaluronic Acid agents | Synjoynt | hyaluronate derivative | J7331 |
| Antineoplastic agent | Synribo | omacetaxine mepesuccinate | J9262 |
| Hyaluronic Acid agents | Synvisc/Synvisc-One | hylan polymer A and B | J7325 |
| Hereditary angioedema medication | Takhzyro | lanadelumab | J0593 |
| CAR-T Therapy | Tecartus | brexucabtagene autoleucel | Q2053; inpatient admin |
| PD1-PDL1 drug | Tecentriq | atezolizumab | J9022 |
| Antineoplastic agent | Tecvayli | teclistamab | J999 (non-specific)/C9148 |

| | | | |
|--|-----------------------------|--------------------------------------|-----------------------------------|
| Ophthalmic injectable | Tepezza | teprotumumab-trbw | J3241 |
| Androgen | Testopel | testosterone pellets-SQ implant | J3490 (non-specific) |
| Antineoplastic agent | Torisel | temsirolimus | J9330 |
| HER-2 receptor drug | Trazimera | trastuzumab-qyyp | Q5116 |
| Antineoplastic agent | Treanda | bendamustine HCl | J9033 |
| Hyaluronic Acid agents | Triluron | hyaluronate derivative | J7332 |
| Hyaluronic Acid agents | TriVisc | hyaluronate derivative | J7329 |
| Antineoplastic agent | Trodelvy | sacituzumab govitecan-hziy | J9317 |
| Immunologic agent | Truxima | rituximab-abbs | Q5115 |
| Multiple sclerosis drug | Tysabri | natalizumab | J2323 |
| Pulmonary arterial hypertension drug | Tyvaso, SubQ or IV infusion | treprostinil | J7686 |
| Monoclonal antibody-Type 1 diabetes | Tzield | teplizumab-mzvw | J3590 (non-specific)/C9149 |
| Complement Inhibitor, monoclonal antibo | Ultomiris | ravulizumab-cwvz | J1303 |
| Antineoplastic agent | Unituxin | dinutuximab | J9999 (non-specific) |
| Monoclonal antibody | Uplizna | inebilizumab-cdon | J1823 |
| Ophthalmic injectable | Vabysmo | faricimab | J2777 |
| Antineoplastic agent | Vectibix | panitumumab | J9303 |
| Antineoplastic agent | Vegzelma | bevacizumab-adcd | Q5129 |
| Pulmonary arterial hypertension drug | Veletri | epoprostenol sodium | J1325 |
| Antisense oligonucleotide | Viltepso | viltolarsen | J1427 |
| Enzyme replacement drug | Vimizim | elosulfase alfa | J1322 |
| Ophthalmic agent | Visudyne | verteporfin | J3396 |
| Antineoplastic agent | Vivimusta | bendamustine HCl | J9999/C9399 |
| Enzyme replacement drug | Vpriv | velaglucerase alfa | J3385 |
| Migraine prophylaxis | Vyepti | eptinezumab-jjmr | J3032 |
| Antisense oligonucleotide | Vyondys-53 | golodirsen | J1429 |
| Antineoplastic agent | Vyxeos | daunorubicin and cytarabine liposome | J9153 |
| Immunoglobulin | Xembify | SC immune globulin | J1558 |
| Enzyme replacement drug | Xenpozyme | olipudase alfa | J0218 (new 4/1/23) |
| Botulinum toxins | Xeomin | incobotulinumtoxin A | J0588 |
| Bone modifying agent | Xgeva | denosumab | J0897 |
| Enzyme-intralesional | Xiaflex | collagenase (systemic) | J0775 |
| Respiratory injectable | Xolair | omalizumab | J2357 |

| | | | |
|--|-----------|-------------------------------|-----------------------|
| Antineoplastic agent | Yervoy | ilipmumab | J9228 |
| CAR-T Therapy | Yescarta | axicabtageneclisoleucel | Q2041;inpatient admin |
| Antineoplastic agent | Yondelis | trabectedin | J9352 |
| Corticosteroid, ophthalmic | Yutiq | fluocinonide acetone implant | J7314 |
| Antineoplastic agent | Zaltrap | ziv-aflibercept | J9400 |
| Antitrypsin deficiency agent | Zemaira | alpha-1 proteinase inhibitor | J0256 |
| Antineoplastic agent | Zepzelca | lurbinectedin | J9223 |
| Corticosteroid, systemic (orthopedic) | Zilretta | triamcinolone | J3304 |
| Antineoplastic agent | Zirabev | bevacizumab-bvzr | Q5118 |
| Spinal muscular atrophy | Zolgensma | onasemnogene abeparvovec-xioi | J3399 |
| Bisphosphonate derivative- Oncology use | Zometa | zoledronic acid | J3489 |